The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Αβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Αβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
